Yahoo Finance RXRX reports insider buying of 24,000 shares by executives, which market observers interpret as confidence in upcoming clinical milestones and strategic partnerships. Operates a GPU-based AI cloud platform, and has several other operations In September 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock surged nearly 7% following progress across key programs and regulatory milestones. A pivotal step was the $12.5 million milestone payment to Rallybio, tied to the advancement of REV102, an investigational ENPP1 inhibitor for the rare disease hypophosphatasia. This achievement underscores the company’s strategy of advancing innovative assets through collaborative development. Yahoo Finance RXRX data indicates market cap at approximately $1.5B, with Q1 revenue up 32% year-over-year. Analysts project short-term upside given the company’s partnership with major pharma for AI-powered pipeline acceleration.